EMEA-002160-PIP01-17

Key facts

Active substance
Serotype 26 adenovirus encoding mosaic 1 HIV-1 group-specific antigen and polymerase proteins (Ad26.Mos1.Gag-Pol) / serotype 26 adenovirus encoding mosaic 2 HIV-1 group-specific antigen and polymerase proteins (Ad26.Mos2.Gag-Pol) / serotype 26 adenovirus encoding mosaic 1 HIV-1 envelope protein (Ad26.Mos1.Env) / serotype 26 adenovirus encoding mosaic 2S HIV-1 envelope protein (Ad26.Mos2S.Env) [Ad26.Mos4.HIV]
Therapeutic area
  • Infectious diseases
  • Vaccines
Decision number
P/0238/2018
PIP number
EMEA-002160-PIP01-17
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Prevention of human immunodeficiency virus (HIV-1) infection
Route(s) of administration
Intramuscular use
Contact for public enquiries
Janssen-Cilag International NV

E-mail: contact@janssen-emea.com
Tel.: +32 14602111

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating